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Insulin resistanceMuscle mitochondrial metabolism is regulated by a number of factors, many of which are responsible for the
transcription of nuclear genes encoding mitochondrial proteins such as PPARδ, PGC-1α or PGC-1β. Recent
evidence indicates that proteins participating in mitochondrial dynamics also regulate mitochondrial
metabolism. Thus, in cultured cells the mitochondrial fusion protein mitofusin 2 (Mfn2) stimulates
respiration, substrate oxidation and the expression of subunits involved in respiratory complexes.
Mitochondrial dysfunction has been reported in skeletal muscle of type 2 diabetic patients. Reduced
mitochondrial mass and defective activity has been proposed to explain this dysfunction. Alterations in
mitochondrial metabolism may be crucial to account for some of the pathophysiological traits that
characterize type 2 diabetes. Skeletal muscle of type 2 diabetic patients shows reduced expression of
PGC-1α, PGC-1β, and Mfn2. In addition, a differential response to bilio-pancreatic diversion-induced weight
loss in non-diabetic and type 2 diabetic patients has been reported. While non-diabetic morbidly obese
subjects showed an increased expression of genes encoding Mfn2, PGC-1α, PGC-1β, PPARδ or SIRT1 in
response to bariatric surgery-induced weight loss, no effect was detected in type 2 diabetic patients. These
observations suggest the existence of a heritable component responsible for the abnormal control of the
expression of genes encoding for modulators of mitochondrial biogenesis/metabolism, and which may
participate in the development of the disease.medicine, C/ Baldiri Reixac 10,
934034717.
A. Zorzano).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Mitochondrial regulatory pathways in skeletal muscle
Mitochondrial metabolism can be modulated via changes in either
cellular mitochondrial mass or by modiﬁcations independent of mass.
Several proteins, such as peroxisome proliferator-activated receptor
γ co-activator-1α (PGC-1α), peroxisome proliferator-activated re-
ceptor γ co-activator-1β (PGC-1β), peroxisome proliferator-activated
receptor δ (PPARδ) and mitofusin 2 (Mfn2), participate in the regu-
lation of mitochondrial biogenesis/function in muscle cells.
PGC-1α and PGC-1β are key positive regulators of mitochondrial
activity and biogenesis in mouse skeletal muscle [1–4]. Gain-of-
function of PGC-1α increases mitochondrial biogenesis and mito-
chondrial activity in skeletal muscle [4,5], in part as a result of the co-
activation of nuclear receptor ERRα (estrogen-related receptor α)
[6–8]. Transgenic mice overexpressing PGC-1α in muscle show an
increased mitochondrial mass [9]. In skeletal muscle, PGC-1β gain-of-
function increases mitochondrial biogenesis and the expression of
genes encoding for mitochondrial proteins through co-activation ofERRα [1,7,10]. The role of PGC-1β under basal non-stimulated
conditions is highlighted by the observation that the expression of
this nuclear co-activator is 28 times higher than that of PGC-1α in
human muscle cells under basal conditions [11]. In keeping with this
view, PGC-1β expression in distinct tissues is unaffected by
physiological processes characterized by increased energy expendi-
ture, such as cold exposure (in brown adipose tissue), fasting (in liver)
and exercise (in muscle). The PGC-1β KO mouse is characterized by a
general defect in the electron transport chain (ETC) system [12–14].
Furthermore, several mitochondrial phenotypes described in PGC-1β-
ablated mice cannot be completely explained by impairment of the
ETC system. For instance, muscle and liver from this mutant mouse
model show reduced mitochondrial volume [12,14]. This decreased
mitochondrial volume together with impaired ETC gene expression
may explain the mitochondrial respiration defect found in muscle
[12].
Muscle-speciﬁc transgenic mice expressing an active form of the
transcription factor PPARδ showmore slow-twitch (type I) ﬁbers than
fast-twitch ones [15]. In addition, this transgenic mouse performs
exercise for longer periods than control mice, thereby demonstrating
the functionality of this change in the proportion of muscle ﬁbers [15].
In keeping with these data, the muscle-speciﬁc PPARδ KO mouse
1029A. Zorzano et al. / Biochimica et Biophysica Acta 1797 (2010) 1028–1033shows an increased number of fast-twitch IIb ﬁbers and a decrease in
slow-twitch type I ﬁbers [16]. PPARδ is co-activated by PGC-1α [17,18]
and, therefore, this co-activation could be part of the mechanism by
which muscle-speciﬁc overexpression of PGC-1α leads to a higher
number of type I ﬁbers [9].
Proteins that participate inmitochondrial fusion or ﬁssion also play
a regulatory role in mitochondrial metabolism. In this regard, skeletal
muscle shows a high abundance of Mfn2 [19–21] and its activity is
crucial in themaintenance ofmitochondrial tubules in culturedmuscle
cells [19]. Mitofusin-2 (Mfn2) protein is a dynamin-related protein
with GTPase activity anchored in the external mitochondrial mem-
brane [22]. Stably transfected ﬁbroblasts with a Mfn2 antisense
sequence show reduced glucose oxidation and a similar reduction in
oxygen consumption [19]. Mfn2 repression mediated by adenoviral
antisense expression in L6E9 myotubes also decreases glucose
oxidation in cultured L6E9 muscle cells [19,23]. Under these condi-
tions, glucose transport and lactate production aremarkedly enhanced
in antisense cells, whereas glucose incorporation into glycogen is
signiﬁcantly depressed [23]. Mfn2 repression is also associated with
decreased rates of pyruvate or palmitate oxidation in L6E9muscle cells
[23] and causes a reduction in mitochondrial membrane potential in
the presence of several oxidative substrates [19,23]. The alterations in
substrate oxidation induced by Mfn2 loss-of-function are not a
consequence of a lower mitochondrial content. These data indicate
thatMfn2 knockdown causes alterations inmitochondrialmetabolism
characterized by reduced mitochondrial membrane potential and
cellular oxygen consumption as well as depressed substrate oxidation,
and under these conditions metabolic homeostasis is maintained by a
higher rate of glucose uptake and glycolysis. The cell with low Mfn2
activity relies on anaerobic glycolysis to generate energy. These results
are in keeping with the observations made in mouse embryonic
ﬁbroblasts with targeted null mutations of bothMfn1 andMfn2. These
cells show loss of mitochondrial membrane potential, reduced
endogenous respiration, and an incapacity to increase respiration
upon the addition of the ionophore 2,4-dinitrophenol [24]. The effect
of Mfn2 gain-of-function on mitochondrial metabolism has also been
studied. Overexpression of Mfn2 in HeLa cells causes perinuclear
aggregation ofmitochondria, amarked enhancement ofmitochondrial
membrane potential and increased glucose oxidation [23]. In order to
determine whether the effects induced by Mfn2 gain-of-function on
mitochondrial activity are related to mitochondrial fusion activity,
studies have been performed with a C-terminal truncated form of
Mfn2 (hMfn2Δ602–757), which no longer has the capacity to induce
mitochondrial fusion. Overexpression of hMfn2Δ602–757 in HeLa
cells does not alter themorphologyofmitochondrialﬁlaments, and the
truncated protein is localized mainly in mitochondria but is also
present in the cytosol. Truncated Mfn2-overexpressing cells show a
marked enhancement of mitochondrial membrane potential and
stimulation of glucose oxidation [23]. These results indicate that
Mfn2 activates mitochondrial metabolism through mechanisms
distinct from the promotion of mitochondrial fusion.2. Muscle mitochondrial metabolism is reduced in type 2 diabetes
Type 2 diabetes is characterized by insulin resistance, which affects
skeletal muscle and other insulin-sensitive tissues, and by defective
insulin secretion. Muscle insulin resistance is manifested by a reduced
capacity of insulin to stimulate glucose uptake due to alterations in
intracellular signalling. In addition to these alterations, insulin-
resistant subjects show a reduced capacity of the muscle to properly
oxidize substrates – glucose and lipids – during fasting conditions and
after a meal [25]. The switch between glucose and lipid oxidation,
depending on energy requirements, is referred to as “metabolic
ﬂexibility” [26]. In this regard, type 2 diabetic subjects showmetabolic
inﬂexibility since they present a higher capacity to oxidize lipids ininsulin-stimulated conditions, instead of switching to glucose oxida-
tion [27,28].
Insulin-resistant conditions are characterized by alterations in
mitochondrial activity in skeletal muscle. Elderly insulin-resistant
subjects show a reduction in mitochondrial oxidative and phosphor-
ylation activity, as assessed by in vivo 13C/31P NMR spectroscopy, and
also increased fat accumulation in muscle and liver [29,30]. The
skeletal muscle of type 2 diabetic patients shows a decrease in the
activity of the Krebs cycle and of the respiratory chain [31]. In keeping
with these observations, plasma levels of lactate are enhanced and the
rate of whole-body lactate production is also increased in these
patients [32,33]. In addition, it has been reported that oral
administration of dichloroacetate to diabetic patients reduces fasting
hyperglycemia, and plasma lactate, cholesterol and triglycerides in
the absence of alterations in circulating insulin [34,35]. Several lines of
evidence suggest that the alterations in mitochondrial metabolism in
skeletal muscle occur before the development of type 2 diabetes.
Thus, offspring of type 2 diabetic parents show reduced ATP synthesis
[29,30], which was the ﬁrst evidence that this could be an inherited
defect.
Several mechanisms may contribute to the reduction of mito-
chondrial activity in insulin-resistant conditions, namely changes in
mitochondrial density or intrinsic alterations in mitochondrial
metabolism. In this regard, there is evidence that insulin-resistant
obese individuals with type 2 diabetes have approximately 30% fewer
mitochondria in their skeletal muscles than age-matched healthy
controls. Thus, the skeletal muscle of type 2 diabetic patients shows a
lower mitochondrial DNA content [36], and these patients also
present reduced citrate synthase activity [31]. It is likely that the
decreased mitochondrial mass is a defect in both obesity and type 2
diabetes. Consequently, no differences in muscle mitochondrial DNA
copy number or in citrate synthase are found inmuscle of obese type 2
diabetic patients compared to non-diabetic obese subjects [37,38]. A
reduced mitochondrial density has been demonstrated in muscle of
insulin-resistant offspring of type 2 diabetic parents [39].
Several studieshave reported that themitochondrial alterations found
in muscle of type 2 diabetic patients reﬂect a functional impairment of
mitochondria since these alterations are present even after correction by
mitochondrial mass [36,38]. However, in other studies, differences in
electron transport chain (ETC)or inoxygen consumptionarenotdetected
after correction by surrogates of mitochondrial mass [31,37]. In all,
current data support the view that mitochondrial mass is decreased in
skeletal muscle in obesity and in type 2 diabetes, and some evidence
supports the notion of a functional impairment of mitochondria.
As previously mentioned, alterations in density and function of
mitochondria have been demonstrated in muscle of insulin-resistant
offspring of type 2 diabetic subjects [30,39]. This observation points to
thepresenceof inheriteddefects that lead tomitochondrial dysfunction;
however, solid demonstration of this hypothesis is still pending.
A reduction in the expression of genes encoding for oxidative
phosphorylation has been proposed to explain the alterations in
mitochondrial metabolism in type 2 diabetes [40,41]. In addition, the
expression of the nuclear co-activators PGC-1α and PGC-1β is reduced
in muscle of type 2 diabetics and in offspring of insulin-resistant
subjects with this disease [40,41]. In this connection, hypermethyla-
tion of PGC-1α within non-CpG nucleotides has been detected in
skeletal muscle from type 2 diabetic patients [42]. The reduced
activity of PGC-1α and PGC-1β may explain, at least in part, the
defective expression of genes encoding respiratory chain subunits and
the lower mitochondrial biogenesis that occurs in muscle in type 2
diabetes [8]. In contrast to these ﬁndings, no changes in PGC-1α or
PGC-1β expression have been reported in diabetic Asian Indians [43].
Type 2 diabetes is also associatedwith reduced expression of genes
involved in oxidative metabolism as well as with the repression of
Mfn2 [44]. Mfn2 loss-of-function reduces glucose oxidation and
mitochondrial membrane potential in muscle and non-muscle cells
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relevant role in thepathophysiology of type 2 diabetes. It isworth noting
that it is unlikely that the dysregulation of Mfn2 expression is a conse-
quence of reduced insulin action. Thus, Mfn2 expression in healthy,
obese or type 2 diabetic subjects is not altered in response to 3 h of
hyperinsulinemia (150 mU/l) during euglycemic–hyperinsulinemic
clamps nor is the expression of this protein affected when cultured
muscle cells are incubated in the presence of supramaximal insulin
concentrations for up to 48 h [44].
Furthermore, it has been shown thatMfn2 is induced by PGC-1α or
by PGC-1β through interaction with the transcription factor ERRα
[45,46]. This may be particularly relevant since it has been reported
that the nuclear co-regulators PGC-1α and PGC-1β are repressed in
type 2 diabetes.
3. Mitochondrial dysfunction and insulin resistance
The association found between insulin-resistant states and mito-
chondrial dysfunction has led to the proposal that a reduced mito-
chondrial metabolism causes insulin resistance. Several intervention
studies have tested this hypothesis and have generated discordant
ﬁndings. Obese/overweight subjects underwent a 4-month interven-
tion in which they performed physical exercise and had further weight
loss induced by dietary restriction. This intervention led to increased
mitochondrial size and stimulated ETC, citrate synthase and succinate
dehydrogenase in muscle, in parallel to ameliorated insulin sensitivity
[47–49]. Similar ﬁndings were reported in type 2 diabetic subjects in
response to weight loss/physical activity intervention [50]. These
studies illustrate that the amelioration of mitochondrial metabolism
and improved insulin sensitivity run in parallel.
In contrast, several other studies indicate that the amelioration of
insulin resistance can occur in the absence of changes inmitochondrial
metabolism. Thus, dietary restriction for 16 weeks caused improved
insulin sensitivity in obese/overweight subjects in the absence of
changes in mitochondrial metabolism or cardiolipin content [51]. In
addition, treatment for 8 weeks with rosiglitazone decreased insulin
resistance in type 2 diabetic patients, without any improvement in
mitochondrial function [52]. Morbidly obese type 2 diabetic patients
and non-diabetic morbidly obese subjects underwent a similar
increase in insulin sensitivity in response to bilio-pancreatic diversion
(BPD) and massive weight loss [53]; however, only the non-diabetic
group showed enhanced expression of genes encoding for mitochon-
drial proteins [53]. Comparison of mitochondrial content and insulin
sensitivity in a range of ethnic groups also casts doubts on a strict
relationship between mitochondrial dysfunction and insulin resis-
tance. Thus, Asian Indians displaying higher mtDNA content and
increased oxidative enzyme activity are more insulin-resistant than
age-, sex- and BMI-matched North American counterparts [43].
Animal studies are also difﬁcult to combine into a coherent picture. A
number of animal models have been generated to ablate PGC-1α or
PGC-1β genes in all tissues or in a tissue-speciﬁcmanner [12–14,54–56].
None of the mouse models generated so far has demonstrated muscle
insulin resistance, in spite of showing alterations in mitochondrial
respiration in this tissue. However, hypomorphic mutation of PGC-1β
causes hepatic insulin resistance [14]. In addition, alteration of
mitochondrial respiration does not necessarily cause insulin resistance.
Thus, the ablation of twomitochondrial proteins inmice, AIF (apoptosis
inducing factor) or Tfam, causes a reduction in the respiratory chain
activity in muscle tissues, without alterations in sensitivity to insulin
[57,58]. Other animal models with alterations in the OXPHOS system,
such as knock-in mice that express a proof-reading-deﬁcient version of
PolgA, the nucleus-encoded catalytic subunit of mtDNA polymerase,
show premature aging and enhanced apoptosis [59,60]. However, it is
unknown whether they develop insulin resistance.
In contrast, some animal models show parallel modiﬁcations in
mitochondrial activity and in insulin sensitivity. Thus, mitochondrialdysfunction caused by long-chain Acyl-CoA dehydrogenase deﬁciency
leads to hepatic steatosis and hepatic insulin resistance in mice [61].
Another example is the mouse lacking malonyl-CoA decarboxylase
(MCD), an enzyme that promotes mitochondrial β-oxidation by
relieving malonyl-CoA-mediated inhibition of carnitine palmitoyl-
transferase 1. MCD KO mice exhibit reduced rates of fat catabolism
and resist diet-induced glucose intolerance despite high intramuscu-
lar levels of long-chain acyl-CoAs. These observations indicate a link
between skeletal muscle insulin resistance and lipid-induced mito-
chondrial stress [62].
The muscle-speciﬁc PPARδ KO mouse shows a reduction in the
abundance of oxidative muscle ﬁbers, repression of the myosin heavy
chain (MHC) isoform I (speciﬁc of type I ﬁbers), and decreased
expression of genes involved in the mitochondrial respiratory chain
and in fatty acid oxidation. These alterations develop earlier than
obesity and insulin resistance [16]. In addition, transgenic mice
overexpressing active PPARδ in skeletal muscle show more oxidative
muscle ﬁbers, and are resistant to obesity and diabetes in response to
a high fat diet [15].
In addition, several lines of experimental evidence suggest that
insulin signalling cascades are crucial formitochondrialmetabolism and
that insulin resistance has a negative impact on mitochondria. Thus, L6
myoblasts regulate the expression of genes encoding the subunits I and
IV of cytochrome-c oxidase in response to insulin [63,64]. Moreover,
chemical inhibition of phosphatidylinositol 3-kinase results in the
repression of citrate synthase expression, a common mitochondrial
enzyme [65]. The most compelling evidence comes from in vivo studies
performed in humans, where administration of insulin to non-diabetic
insulin-sensitive subjects caused an increase in the rate ofmitochondrial
ATPproduction; aneffect thatwasnot observed indiabetic patients [66].
It has also been reported that musclemitochondrial protein synthesis is
stimulated by insulin treatment [66,67] and that this process is also
impaired in diabetic subjects [68].
These ﬁndings reveal that insulin signalling has a direct impact
on mitochondrial metabolism in humans. This notion is corrobo-
rated by several studies performed in animal models. Thus, in
genetically engineered mice, homozygous deletions of the insulin
receptor results in early lethality [69]; however, a mosaic animal
model with a 98% reduction of insulin receptors displays enlarged
mitochondria that show poorly organized cristae. These animals
show reduced expression of PPARγ, PGC1α and UCP1 [70], sur-
prisingly without the characteristics of the insulin resistance
phenotype (β-cell hyperplasia, obesity, and dyslipidemia). Mice
with cardiomyocyte deletion of insulin receptors show respiratory
defects for pyruvate, reduction in catalytic subunits of pyruvate
dehydrogenase, as well as decreased oxygen consumption and ATP
synthesis. Thus, impaired myocardial insulin signalling promotes an
altered mitochondrial energetics [71].
In all, thedata available onhumans indicate thatnot all interventions
that improve insulin sensitivity are a consequence of parallel changes in
musclemitochondrial activity. In addition, animal studies show that not
all alterations inmusclemitochondrial activity lead to insulin resistance;
in fact, manipulations of mitochondrial lipid metabolism may be more
directly related to the development of insulin resistance. On the basis of
these observations, it is highly relevant: a) to identify the speciﬁc
mechanisms that operate in mitochondria and that lead to insulin
resistance; and b) to identify potential compensatory mechanisms
that may prevent insulin resistance in the presence of mitochondrial
dysfunction.
4. Speciﬁc alterations in morbidly obese type 2 diabetic subjects
Weight reduction and physical exercise are the best approaches to
ameliorate insulin sensitivity; however, compliance with lifestyle
changes has proven to have little beneﬁcial effect. In recent decades,
bariatric surgery has emerged as a potential therapy for diabetes [72].
Fig. 1. Scheme of the changes in gene expression that occur in non-diabetic (panel A) and type 2 diabetic subjects (panel B) in response to bilio-pancreatic diversion (BPD).
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weight loss mainly as a result of lipid malabsorption [73,74]. BPD
causes a net improvement in insulin sensitivity, long before the
normalization of body weight [75]. In addition, BPD regulates
substrate oxidation, and modulates the expression of genes involved
in lipid synthesis [76,77] and oxidation [76,78] in both muscle and
adipose tissue.
BPD intervention has been instrumental in the identiﬁcation of
speciﬁc alterations in morbidly obese type 2 diabetic patients. Non-
diabetic and type 2 diabetic morbidly obese subjects responded to
BPD by losing weight to a similar extent, improving insulin sensitivity,
and lowering glycemia, insulinemia, and the plasma concentration of
cholesterol and triglycerides [53]. Under these conditions, in which
both groups showed a similar clinical biochemistry, non-diabetic
subjects showed a higher rate of glucose oxidation and lower lipid
oxidation than diabetic patients [53]. Furthermore, in response to
BPD, non-diabetic subjects showed an induced expression of genes
encoding for mitochondrial proteins (Mfn2, citrate synthase or porin),
and regulatory proteins (PGC-1α, PGC-1β, PPARδ, or SIRT1) (Fig. 1).
However, under similar conditions, diabetic patients did not show any
increase in the expression of these genes [53]. We propose that the
pattern of changes in gene expression detected in skeletal muscle in
response to BPD serves to trigger mitochondrial biogenesis in skeletal
muscle, thereby favoring increased glucose oxidation, under condi-
tions of reduced lipid availability (Fig. 1). This notion requires
conﬁrmation by direct analysis in muscle but is consistent with
observations that whole-body glucose oxidation is increased in
subjects after BPD. Subjects undergoing BPD show reduced lipid
availability provided that BPD causes lipid malabsorption. This
observation probably accounts for the detection of lower whole-
body lipid oxidation after BPD in non-diabetic subjects.
These ﬁndings suggest that weight loss induced by BPD exerts a
beneﬁcial effect on insulin sensitivity via mechanisms that are
independent of the skeletal muscle expression of genes involved in
mitochondrial biogenesis/function. Furthermore, the observation that
gene expression is not altered with weight loss in type 2 diabetic
patients while it is induced in subjects with normal glucose-tolerance
points to the contribution of a heritable component.Acknowledgements
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